The Wall Street Journal podcast stated in an episode on the 7th that China's biotechnology industry has been developing rapidly in recent times, with characteristics such as low cost and high efficiency. This is similar to the "DeepSeek moment" that has attracted much attention in the field of artificial intelligence, and China's biotechnology industry is also ushering in the "DeepSeek moment". The program cites data from DealForma, a research institution in the biopharmaceutical industry, stating that in 2020, less than 5% of pharmaceutical industry transactions worth $50 million or more involved China; And this proportion has risen to nearly 30% by 2024. The program predicts that in ten years, many drugs on the US market may come from Chinese laboratories. This is related to multiple factors, such as China now having an increasing number of top scientists, a large number of well-trained professionals in industries such as chemistry, and relatively low research and development costs. Another important reason is that the Chinese government attaches great importance to and strongly supports the development of the biopharmaceutical industry, resulting in higher approval efficiency in clinical trials, drug launches, and other aspects. This enables Chinese companies to conduct clinical trials faster and at lower costs. The program states that key drugs being developed by Chinese companies include cancer and obesity treatment drugs. These drugs may not necessarily be more innovative than the research and development achievements of similar companies in the United States, but they excel in high efficiency and low cost, which is similar to the development model of Chinese enterprise DeepSeek in the field of artificial intelligence. The program believes that the rapid development of China's biotechnology field has been welcomed by some large international pharmaceutical companies, because instead of investing heavily in acquiring small and medium-sized enterprises engaged in pharmaceutical research and development in the United States or Europe, it is better to seek opportunities in China. Related companies have begun to recognize this opportunity, and we will see more similar transactions